A double punch for plasma cell leukemia.
作者信息
Kaiser Martin
机构信息
The Institute of Cancer Research, London, UK The Royal Marsden Hospital, London.
出版信息
Haematologica. 2023 Apr 1;108(4):939-940. doi: 10.3324/haematol.2022.281353.
Abstract
摘要
相似文献
1
A double punch for plasma cell leukemia.浆细胞白血病的双重打击。
Haematologica. 2023 Apr 1;108(4):939-940. doi: 10.3324/haematol.2022.281353.
2
[Acute plasma cell leukemia with a Philadelphia chromosome (Ph1)].伴费城染色体（Ph1）的急性浆细胞白血病
Rinsho Ketsueki. 1987 Jun;28(6):891-6.
3
Plasma cell leukemia mimicking acute myeloid leukemia.酷似急性髓系白血病的浆细胞白血病
Blood. 2016 May 12;127(19):2359. doi: 10.1182/blood-2016-02-698084.
4
[A case of plasma cell leukemia. Clinical and cytogenetic observations].[浆细胞白血病一例。临床及细胞遗传学观察]
Orv Hetil. 1985 Oct 13;126(41):2531-3.
5
Primary plasma cell leukemia and multiple myeloma: one or two diseases according to the methodology.
Blood. 1999 Nov 15;94(10):3607-9.
6
A classic presentation of an uncommon leukemia.一种罕见白血病的典型表现。
Am J Hematol. 2013 May;88(5):431-2. doi: 10.1002/ajh.23325. Epub 2012 Sep 17.
7
A case of plasma cell leukemia superimposed on Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia.
Am J Hematol. 1991 Mar;36(3):222-3. doi: 10.1002/ajh.2830360317.
8
[Physiopathological and cytogenetic findings in 2 cases of plasma cell leukemia].2例浆细胞白血病的生理病理学及细胞遗传学研究结果
Minerva Med. 1970 May 19;61(37):2005-12.
9
Plasmablastic crisis of Philadelphia chromosome-positive chronic myeloid leukemia.
Ann Hematol. 2010 Jun;89(6):641-2. doi: 10.1007/s00277-009-0852-1. Epub 2009 Oct 21.
10
Pathologic quiz case: a 43-year-old man with fatigue and night sweats.病理问答病例：一名43岁有疲劳和盗汗症状的男子。
Arch Pathol Lab Med. 2001 Jun;125(6):838-40. doi: 10.5858/2001-125-0838-PQCAYO.
本文引用的文献
1
Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling.原发性浆细胞白血病患者的自体和同种异体造血细胞移植策略比较，并进行动态预测建模。
Haematologica. 2023 Apr 1;108(4):1105-1114. doi: 10.3324/haematol.2021.280568.
2
Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study.新诊断的年轻或高危骨髓瘤患者接受双次自体/同种异体移植后接受硼替佐米维持治疗的结果：一项 II 期研究。
Bone Marrow Transplant. 2022 Feb;57(2):252-260. doi: 10.1038/s41409-021-01532-2. Epub 2021 Nov 29.
3
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.西达基奥仑赛，一种针对 B 细胞成熟抗原的嵌合抗原受体 T 细胞疗法，用于治疗复发或难治性多发性骨髓瘤患者（CARTITUDE-1）：一项 1b/2 期开放标签研究。
Lancet. 2021 Jul 24;398(10297):314-324. doi: 10.1016/S0140-6736(21)00933-8. Epub 2021 Jun 24.
4
MUK OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia.MUK OPTIMUM 方案：一项筛查研究，旨在识别适合新型治疗方法的多发性骨髓瘤高危患者，并结合一项 II 期研究，评估新型生物治疗联合方案在初诊高危多发性骨髓瘤和浆细胞白血病中的疗效。
BMJ Open. 2021 Mar 24;11(3):e046225. doi: 10.1136/bmjopen-2020-046225.
5
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.硼替佐米、来那度胺和地塞米松联合或不联合依洛珠单抗治疗未经治疗的高危多发性骨髓瘤患者（SWOG-1211）：一项随机、2 期试验的主要分析。
Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22.
6
Emerging immunotherapies in multiple myeloma.多发性骨髓瘤的新兴免疫疗法。
BMJ. 2020 Sep 21;370:m3176. doi: 10.1136/bmj.m3176.
7
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.芦可替尼治疗糖皮质激素难治性急性移植物抗宿主病。
N Engl J Med. 2020 May 7;382(19):1800-1810. doi: 10.1056/NEJMoa1917635. Epub 2020 Apr 22.
Zotero 插件